why choose us

Clinical Trials Search

Showing 16,020 of 132,963 result(s)
A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Status: Completed

Condition: Primary Membranous Nephropathy

Interventions: Participants will receive zanubrutinib once daily

Date: 2023-01-23

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Status: NOT_YET_RECRUITING

Condition: Sickle Cell Disease

Interventions: The study intervention is etavopivat (400 mg), administered orally and once daily (QD)

Date: 2023-01-23

EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Status: Completed

Condition: Epidermolysis Bullosa

Interventions:

EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expre

Date: 2023-01-23

Effect of Transpulmonary Pressure Guided Ventilation on Intraoperative Right Heart Function

Status: NOT_YET_RECRUITING

Condition: Obesity

Interventions:

Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal ma

Date: 2023-01-23

HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2

Status: Completed

Condition: Major Depressive Disorder

Interventions: Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD).
A highly trained masters

Date: 2023-01-23

Lucid Registry Study

Status: Completed

Condition: Barrett Esophagus

Interventions: EsoCheck® (EC) is an FDA 510(k) cleared device that is indicated for use in the collection and retrieval of surface cells of the esophagus in the gene

Date: 2023-01-23

International Rare Brain Tumor Registry

Status: Completed

Condition: Astroblastoma

Interventions:

Date: 2023-01-23

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Status: Completed

Condition: Advanced Cholangiocarcinoma

Interventions: TAS-120 is an oral FGFR inhibitor

Date: 2023-01-23

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Status: Completed

Condition: Hepatic Impairment

Interventions: Specified dose on specified days

Date: 2023-01-23

RISC Panel Remnant Sample Collection

Status: Completed

Condition: Arthritis, Inflammatory

Interventions: The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments [CLIA] Registratio

Date: 2023-01-23